bevacizumab + cisplatin + docetaxel + pemetrexed

A combination chemotherapy regimen consisting of bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor), cisplatin (a platinum-based chemotherapeutic agent), docetaxel (a taxane chemotherapeutic agent), and pemetrexed (an antifolate antineoplastic agent). This combination is primarily used in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). The regimen typically involves an induction phase with cisplatin, pemetrexed, and bevacizumab followed by a maintenance phase with docetaxel and bevacizumab. Bevacizumab inhibits angiogenesis by targeting VEGF, while the chemotherapeutic agents (cisplatin, docetaxel, and pemetrexed) target rapidly dividing cancer cells through different mechanisms.